Emergent BioSolutions (EBS) Tops Q3 EPS by 27c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 +2.04%
Revenue Growth %: +32.0%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +32.0%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.68, $0.27 better than the analyst estimate of $0.41. Revenue for the quarter came in at $149.4 million versus the consensus estimate of $124.55 million.
Full Year 2017 Forecast
Full Year 2017 Forecast
Taking into account the year-to-date performance as well as our recent acquisitions and other news flow, the company is raising its financial forecast for the full year to reflect the strength of the company’s operations.
| (in millions) | Previous | ||
| $540 to $560 | BioThrax® | $265 to $280 | |
| $70 to $80 | Adjusted Net Income (1) | $70 to $80 | |
| $150 to $160 | $135 to $145 |
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
